In a direct-to-consumer market optimized for speed and price, Precision Telemed made a deliberate decision to absorb costs its competitors cut. Founder JP Rius argues that the expense of quality is not a liability on the balance sheet — it is the business.

There is a version of direct-to-consumer telehealth engineered to be as cheap to operate as possible. Intake happens through an automated questionnaire. A provider reviews it asynchronously, often in seconds. A prescription is issued. The patient may never speak to a human being. The model is fast, it scales beautifully, and its margins are excellent.

Precision Telemed, a nationwide telehealth platform offering GLP-1 weight loss programs, testosterone replacement therapy, NAD+ therapy, and other physician-led treatment programs, deliberately chose not to build that version. According to founder JP Rius, that decision is the single most important one the company has made.

The Line Item Most Competitors Try to Eliminate

Rius comes from pharmaceutical commercial operations — a background spanning drug commercialization, sales force launches, and supply chain trade. It makes him unusually attentive to where costs sit in a healthcare business, and where cutting them creates hidden liabilities.

“There is a real, measurable cost of quality,” Rius says. “Every decision we make to do something the right way instead of the cheap way shows up as an expense. Compliance infrastructure costs money. Real provider oversight costs money. Building an actual relationship with a patient costs more than automating them through a form. We treat that cost as the most important investment we make, not a number to minimize.”

That runs against the logic of the category. Much of the direct-to-consumer health boom has been built on stripping human interaction out of care delivery, because human interaction is the most expensive variable in the model. For a company optimizing purely for margin and growth velocity, the incentives all point toward less.

Why Video Visits, When the Math Says Skip Them

The clearest example is Precision Telemed’s use of video visits. Many competitors have moved to fully asynchronous models precisely because live video is expensive: it requires provider time, scheduling infrastructure, and slower throughput than a questionnaire reviewed in bulk. Every video visit is a cost the async model does not carry.

Precision Telemed keeps them anyway, because Rius believes the relationship they build is not optional to good care.

“When a provider and a patient actually see each other, talk, and build a relationship, the entire quality of care changes,” he says. “The provider catches things a form never would. The patient trusts the process and stays engaged with their own health. That relationship is the foundation of good medicine, and you cannot build it through a checkbox.”

The financial logic is subtler than it looks. A video visit costs more per patient in the near term. But the relationship it establishes drives the outcomes that determine the long-term economics of a subscription healthcare business: whether patients stay, whether they succeed, and whether they trust the company enough to remain customers. In a business where retention is everything, the expensive touchpoint is not a cost center. It is the retention engine.

Affordability and Quality as a Deliberate Balance

The counterintuitive part is that Precision Telemed pairs this insistence on quality with a commitment to affordability. Its programs are priced well below traditional in-person clinics, and the model is entirely cash-pay, with no insurance required.

Reconciling those commitments is where operational discipline comes in. Precision Telemed offsets the cost of quality not by cutting the care, but by owning its technology infrastructure and eliminating the overhead that inflates prices elsewhere in the industry. The savings from operating efficiently are passed to patients, while the spending on quality and relationships is protected.

“Affordable and high-quality are not opposites,” Rius says. “The industry treats them like a tradeoff because the easiest way to lower price is to lower quality. We took the cost out of the places that do not touch the patient, and we protected the spending in the places that do.”

The Compliance Pillar

The same philosophy governs compliance, an area where cutting corners is both cheaper and increasingly common. The direct-to-consumer prescribing space has drawn intensifying regulatory scrutiny. Rius, given his pharmaceutical trade background, treats compliance as non-negotiable infrastructure rather than a box to check — a posture that carries real cost in documentation, conservative prescribing, and licensed provider oversight.

“Compliance is not separate from quality. It is quality,” he says. “The companies cutting those corners are making a short-term financial decision that eventually comes due. We would rather carry the cost now than the liability later.”

The Bet

Precision Telemed has served more than 5,000 patients, operates in all 50 states, and is LegitScript-certified. It is family-owned and was built without major outside capital, which Rius says gives it freedom to make long-horizon decisions a venture-backed competitor under margin pressure might not.

The larger bet is a wager about where healthcare businesses ultimately win. In a category whose dominant strategy has been to automate, minimize, and race to the lowest price, Precision Telemed is arguing that the durable advantage belongs to the company willing to spend on what actually makes care good: real relationships, real oversight, and real compliance.

“The cost of quality is the best money we spend,” Rius says. “Everything else is negotiable. That is not.”